Dissolution and bracketing (EMA) [Regulatives / Guidelines]

posted by wienui  – Germany/Oman, 2020-04-04 10:42 (1745 d 14:45 ago) – Posting: # 21315
Views: 3,263

Hi Susan,

All the General biowaiver criteria are fulfilled except the f2 similarity is not achieved between the highest strength (used in BE study) and the lower strengths


I see from your post above that you had tried to use same dose comparison (2 x 5 mg vs 10 mg), but it didn't help.

❝ Do I need to do a BE study on all the strengths that are not showing similarity in dissolution


No you don't need if you intended to use the bracketing approach.

What about the similarity in dissolution between the lower strengths for which BE were not conducted, are They similar or there were dissolution differences?

If there are similar between each others, then as you mentioned just perform one BE study for the strength differing most in dissolution with the highest strength (EMA).

In your place I will try to take EMA scientific advice, but you have to keep in mind that any scientific advice or protocol assistance given is not legally binding with regard to any future marketing authorisation application of the product concerned, either on the Agency/CHMP/COMP, or on the Applicant.

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
23,362 posts in 4,906 threads, 1,674 registered users;
132 visitors (0 registered, 132 guests [including 10 identified bots]).
Forum time: 00:27 CET (Europe/Vienna)

You are rewarding a teacher poorly
if you remain always a pupil.    Friedrich Nietzsche

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5